Novartis Ag (NVS) 82.03 $NVS
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Globe Newswire - Wed Jul 13, 2:43PM CDT
Novartis International AG / Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.03 (+0.35)
Top 7 Research Reports for July 11, 2016
Sheraz Mian - Zacks Investment Research - Mon Jul 11, 12:50PM CDT
Top 7 Research Reports for July 11, 2016
GILD: 85.75 (-0.88), MO: 69.08 (+0.21), PG: 85.89 (+0.14), SO: 53.13 (+0.29), NVS: 82.03 (+0.35)
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 41.97 (-0.50), PFE: 36.31 (+0.07), EXEL: 8.04 (-0.10), NVS: 82.03 (+0.35)
Health Canada approves oral treatment (Pr)AFINITOR® (everolimus) for progressive, non-functional GI and lung neuroendocrine tumours (NET)
CNW Group - Mon Jul 11, 4:59AM CDT
Novartis today announced that Health Canada has approved AFINITOR(® )(everolimus) tablets for the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease.(3)
NVS: 82.03 (+0.35)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), NVS: 82.03 (+0.35)
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
PR Newswire - Thu Jul 07, 3:40PM CDT
Novartis today announced that the US Food and Drug Administration (FDA) has approved an expanded age range for Xolair® (omalizumab) to include children six to 11 years of age with moderate to severe persistent asthma, having a positive skin test or in vitro reactivity to an airborne allergen (perennial aeroallergen) and symptoms that are inadequately controlled with inhaled corticosteroids4. The previous age range for the asthma indication of Xolair was 12 years and older. This approval comes three months ahead of the FDA action date.
NVS: 82.03 (+0.35)
UCB's Vimpat Approved in Japan for Partial Onset Seizures
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:47AM CDT
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
JNJ: 123.00 (+0.08), ABBV: 64.77 (-0.73), NVS: 82.03 (+0.35)
Ignyta Appoints Dr. Christian V. Kuhlen as General Counsel
BusinessWire - Tue Jul 05, 8:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Dr. Christian V. Kuhlen has been appointed to serve as its General Counsel and Secretary, replacing Matt Onaitis. Since 2007, Dr. Kuhlen served as General Counsel, Vice President and Secretary of Genoptix, Inc., where he led the legal and corporate governance functions from its initial public offering in 2007, through its successful acquisition by Novartis in 2011. Following the completion of Genoptix's acquisition, Dr. Kuhlen continued to serve the company in these capacities, as well as leading its internal public policy function. Prior to joining Genoptix, Dr. Kuhlen was an attorney in private practice with Cooley LLP from October 2004 to September 2007. Dr. Kuhlen holds a B.S. in Biochemistry and Cell Biology and a B.A. in Economics from the University of California, San Diego, and a J.D. and M.D. from the University of Southern California.
RXDX: 5.72 (-0.13), NVS: 82.03 (+0.35)
Research and Markets - Global Chronic Lymphocytic Leukemia Market CAGR Growth of 19.16% by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AbbVie, Amgen, Novartis
PR Newswire Europe - Tue Jul 05, 7:11AM CDT
DUBLIN, July 5, 2016 /PRNewswire/ --
NVS: 82.03 (+0.35)
China COPD Drugs Market Growth of 15.56% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AstraZeneca, GSK, Novartis - Research and Markets
BusinessWire - Tue Jul 05, 6:36AM CDT
Research and Markets has announced the addition of the "COPD Drugs Market in China 2016-2020" report to their offering.
NVS: 82.03 (+0.35)
AMENDED MEDIA RELEASE - This is an Amended Media Release further to Novartis Pharmaceuticals Canada Inc.'s ("Novartis"
Media Release issued on January 7, 2015 for Fluad Pediatric®.
CNW Group - Mon Jul 04, 6:59AM CDT
On November 28, 2014, Fluad Pediatric(® )designed specifically for infants was authorized for sale in Canada
NVS: 82.03 (+0.35)
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
Globe Newswire - Mon Jul 04, 12:31AM CDT
MorphoSys AG / MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.03 (+0.35)
Novartis' Systemic Mastocytosis Drug Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:43PM CDT
Novartis AG (NVS) announced that data from its phase II study, CPKC412D2201, on PKC412 (midostaurin) was published in The New England Journal of Medicine.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38), NVS: 82.03 (+0.35)
Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer
BusinessWire - Thu Jun 30, 8:00AM CDT
Jaguar Animal Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company", an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that it has appointed Dr. Roger Waltzman as Chief Scientific Officer.
JAGX: 1.89 (-0.01), NVS: 82.03 (+0.35)
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 5:20PM CDT
Shares of Xencor, Inc. (XNCR) rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Novartis AG (NVS).
PFE: 36.31 (+0.07), AMGN: 160.52 (-1.44), XNCR: 18.19 (-0.10), NVS: 82.03 (+0.35)
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
PR Newswire - Wed Jun 29, 4:15PM CDT
Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval [CI], 49-70%; P<0.001) in patients with advanced systemic mastocytosis (SM). The median duration of response for all responders in the primary efficacy population was 24.1 months (95% CI, 10.8-not estimated [NE])1.
NVS: 82.03 (+0.35)
SmarTrend Watching for Potential Pullback in Shares of Novartis After 2.24% Gain
Comtex SmarTrend(R) - Wed Jun 29, 2:05PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $80.91 to a high of $81.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $79.63 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVS: 82.03 (+0.35)
Global Non-Hodgkin Lymphoma Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Merck, Novartis - Research and Markets
BusinessWire - Wed Jun 29, 8:16AM CDT
Research and Markets has announced the addition of the "Non-Hodgkin Lymphoma - Pipeline Review, H1 2016" report to their offering.
NVS: 82.03 (+0.35)
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
PR Newswire - Wed Jun 29, 6:15AM CDT
Novartis today released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85% of U.S. respondents have suffered from social stigma like discrimination and humiliation because of their disease. In addition, U.S. results from the global survey show that 52% of psoriasis patients do not believe clear skin is a realistic goal for them.1
NVS: 82.03 (+0.35)
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Globe Newswire - Wed Jul 13, 2:43PM CDT
Novartis International AG / Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.03 (+0.35)
Top 7 Research Reports for July 11, 2016
Sheraz Mian - Zacks Investment Research - Mon Jul 11, 12:50PM CDT
Top 7 Research Reports for July 11, 2016
GILD: 85.75 (-0.88), MO: 69.08 (+0.21), PG: 85.89 (+0.14), SO: 53.13 (+0.29), NVS: 82.03 (+0.35)
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 41.97 (-0.50), PFE: 36.31 (+0.07), EXEL: 8.04 (-0.10), NVS: 82.03 (+0.35)
Health Canada approves oral treatment (Pr)AFINITOR® (everolimus) for progressive, non-functional GI and lung neuroendocrine tumours (NET)
CNW Group - Mon Jul 11, 4:59AM CDT
Novartis today announced that Health Canada has approved AFINITOR(® )(everolimus) tablets for the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease.(3)
NVS: 82.03 (+0.35)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), NVS: 82.03 (+0.35)
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
PR Newswire - Thu Jul 07, 3:40PM CDT
Novartis today announced that the US Food and Drug Administration (FDA) has approved an expanded age range for Xolair® (omalizumab) to include children six to 11 years of age with moderate to severe persistent asthma, having a positive skin test or in vitro reactivity to an airborne allergen (perennial aeroallergen) and symptoms that are inadequately controlled with inhaled corticosteroids4. The previous age range for the asthma indication of Xolair was 12 years and older. This approval comes three months ahead of the FDA action date.
NVS: 82.03 (+0.35)
UCB's Vimpat Approved in Japan for Partial Onset Seizures
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:47AM CDT
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
JNJ: 123.00 (+0.08), ABBV: 64.77 (-0.73), NVS: 82.03 (+0.35)
Ignyta Appoints Dr. Christian V. Kuhlen as General Counsel
BusinessWire - Tue Jul 05, 8:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Dr. Christian V. Kuhlen has been appointed to serve as its General Counsel and Secretary, replacing Matt Onaitis. Since 2007, Dr. Kuhlen served as General Counsel, Vice President and Secretary of Genoptix, Inc., where he led the legal and corporate governance functions from its initial public offering in 2007, through its successful acquisition by Novartis in 2011. Following the completion of Genoptix's acquisition, Dr. Kuhlen continued to serve the company in these capacities, as well as leading its internal public policy function. Prior to joining Genoptix, Dr. Kuhlen was an attorney in private practice with Cooley LLP from October 2004 to September 2007. Dr. Kuhlen holds a B.S. in Biochemistry and Cell Biology and a B.A. in Economics from the University of California, San Diego, and a J.D. and M.D. from the University of Southern California.
RXDX: 5.72 (-0.13), NVS: 82.03 (+0.35)
Research and Markets - Global Chronic Lymphocytic Leukemia Market CAGR Growth of 19.16% by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AbbVie, Amgen, Novartis
PR Newswire Europe - Tue Jul 05, 7:11AM CDT
DUBLIN, July 5, 2016 /PRNewswire/ --
NVS: 82.03 (+0.35)
China COPD Drugs Market Growth of 15.56% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AstraZeneca, GSK, Novartis - Research and Markets
BusinessWire - Tue Jul 05, 6:36AM CDT
Research and Markets has announced the addition of the "COPD Drugs Market in China 2016-2020" report to their offering.
NVS: 82.03 (+0.35)
AMENDED MEDIA RELEASE - This is an Amended Media Release further to Novartis Pharmaceuticals Canada Inc.'s ("Novartis"
Media Release issued on January 7, 2015 for Fluad Pediatric®. CNW Group - Mon Jul 04, 6:59AM CDT
On November 28, 2014, Fluad Pediatric(® )designed specifically for infants was authorized for sale in Canada
NVS: 82.03 (+0.35)
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
Globe Newswire - Mon Jul 04, 12:31AM CDT
MorphoSys AG / MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.03 (+0.35)
Novartis' Systemic Mastocytosis Drug Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:43PM CDT
Novartis AG (NVS) announced that data from its phase II study, CPKC412D2201, on PKC412 (midostaurin) was published in The New England Journal of Medicine.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38), NVS: 82.03 (+0.35)
Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer
BusinessWire - Thu Jun 30, 8:00AM CDT
Jaguar Animal Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"
, an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that it has appointed Dr. Roger Waltzman as Chief Scientific Officer. JAGX: 1.89 (-0.01), NVS: 82.03 (+0.35)
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 5:20PM CDT
Shares of Xencor, Inc. (XNCR) rallied 32.06% after the company announced that it has entered into a collaboration and license agreement with Novartis AG (NVS).
PFE: 36.31 (+0.07), AMGN: 160.52 (-1.44), XNCR: 18.19 (-0.10), NVS: 82.03 (+0.35)
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
PR Newswire - Wed Jun 29, 4:15PM CDT
Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval [CI], 49-70%; P<0.001) in patients with advanced systemic mastocytosis (SM). The median duration of response for all responders in the primary efficacy population was 24.1 months (95% CI, 10.8-not estimated [NE])1.
NVS: 82.03 (+0.35)
SmarTrend Watching for Potential Pullback in Shares of Novartis After 2.24% Gain
Comtex SmarTrend(R) - Wed Jun 29, 2:05PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $80.91 to a high of $81.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $79.63 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVS: 82.03 (+0.35)
Global Non-Hodgkin Lymphoma Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Merck, Novartis - Research and Markets
BusinessWire - Wed Jun 29, 8:16AM CDT
Research and Markets has announced the addition of the "Non-Hodgkin Lymphoma - Pipeline Review, H1 2016" report to their offering.
NVS: 82.03 (+0.35)
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
PR Newswire - Wed Jun 29, 6:15AM CDT
Novartis today released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85% of U.S. respondents have suffered from social stigma like discrimination and humiliation because of their disease. In addition, U.S. results from the global survey show that 52% of psoriasis patients do not believe clear skin is a realistic goal for them.1
NVS: 82.03 (+0.35)
